Data gathered: November 27
Alternative Data for Longboard Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 75 | Sign up | Sign up | Sign up |
| Webpage traffic | 10,000 | Sign up | Sign up | Sign up |
| Google Trends | 3 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 902 | Sign up | Sign up | Sign up |
| Twitter Mentions | 32 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs for neurological diseases. The company is headquartered in San Diego, California.
| Price | $59.96 |
| Target Price | Sign up |
| Volume | 672,230 |
| Market Cap | $2.33B |
| Year Range | $17 - $59.97 |
| Dividend Yield | 0% |
| Analyst Rating | 29% buy |
| Industry | Biotechnology |
In the news
 |
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Receives $59.56 Average PT from BrokeragesNovember 24 - ETF Daily News |
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic EncephalopathiesNovember 12 - Finnhub |
|
 |
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)November 11 - Yahoo |
 |
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNovember 7 - Yahoo |
Longboard Pharmaceuticals : Reports Third Quarter 2024 Financial Results and Provides Corporate Updates Form 8 KNovember 7 - Finnhub |
|
|
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Receives Consensus Rating of “Hold” from BrokeragesNovember 2 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 6.7M | -6.7M | -25M | -28M | -0.630 |
| Q2 '24 | 0 | 5.2M | -5.2M | -22M | -26M | -0.560 |
| Q1 '24 | 0 | 4.9M | -4.9M | -15M | -18M | -0.420 |
| Q4 '23 | 8,000 | 3.4M | -3.4M | -15M | -16M | -0.620 |
| Q3 '23 | 0 | 3.1M | -3.1M | -13M | -14M | -0.550 |
Insider Transactions View All
| Kaye Randall filed to sell 17,920 shares at $59. October 16 '24 |
| Kaye Randall filed to sell 19,820 shares at $33.1. September 16 '24 |
| Kaye Randall filed to sell 17,920 shares at $34. September 16 '24 |
| Kaye Randall filed to sell 21,020 shares at $31.8. September 16 '24 |
| Kaye Randall filed to sell 25,220 shares at $30.9. September 16 '24 |
Similar companies
Read more about Longboard Pharmaceuticals (LBPH) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Longboard Pharmaceuticals?
The Market Cap of Longboard Pharmaceuticals is $2.33B.
What is the current stock price of Longboard Pharmaceuticals?
Currently, the price of one share of Longboard Pharmaceuticals stock is $59.96.
How can I analyze the LBPH stock price chart for investment decisions?
The LBPH stock price chart above provides a comprehensive visual representation of Longboard Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Longboard Pharmaceuticals shares. Our platform offers an up-to-date LBPH stock price chart, along with technical data analysis and alternative data insights.
Does LBPH offer dividends to its shareholders?
As of our latest update, Longboard Pharmaceuticals (LBPH) does not offer dividends to its shareholders. Investors interested in Longboard Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Longboard Pharmaceuticals?
Some of the similar stocks of Longboard Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.